Physician profile
James Cs Hahn
NPI 1033293634
$5,480.43
in general payments reported to CMS, 2019-2025
23 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $702 · 2020: $704 · 2021: $594 · 2022: $847 · 2023: $797 · 2024: $760 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,634.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,453.38 | 2019-2025 | |
| Abbvie INC. | $919.42 | 2019-2025 | |
| Amgen INC. | $638.50 | 2019-2025 | Prolia, Evenity, Repatha |
| Lilly USA, LLC | $389.30 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Abbott Laboratories | $322.84 | 2022-2025 | Assurity, Proclaim |
| Janssen Pharmaceuticals, INC | $302.82 | 2019-2021 | |
| Novo Nordisk INC | $232.42 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.90 | 2019-2023 | Jardiance |
| Aimmune Therapeutics, INC. | $134.58 | 2025 | Zenpep, Vowst |
| Pfizer INC. | $128.75 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $114.15 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $104.57 | 2021-2024 | |
| Dexcom, INC. | $102.40 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $92.30 | 2019-2020 | |
| Esperion Therapeutics, INC. | $87.12 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $70.02 | 2019-2020 | |
| Glaxosmithkline, LLC. | $54.68 | 2023-2024 | Shingrix, Arexvy |
| Radius Health, INC. | $30.36 | 2019 | |
| Madrigal Pharmaceuticals | $26.08 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $22.97 | 2024 | Voquezna |
| Exact Sciences Corporation | $22.61 | 2024 | Cologuard Collection Kit |
| Arbor Pharmaceuticals, INC. | $20.28 | 2019 | |
| Hologic Sales and Service, LLC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Hahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.